These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1014 related items for PubMed ID: 16186518

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ, Nurmikko TJ, Young CA.
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [Abstract] [Full Text] [Related]

  • 3. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
    Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, Giacomelli E, Gabriele M, Aragona M, Tomassini V, Pantano P, Pozzilli C, Inghilleri M.
    Eur J Pain; 2009 May; 13(5):472-7. PubMed ID: 18603457
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
    Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, Pantano P, Pozzilli C, Inghilleri M.
    Clin Neuropharmacol; 2009 May; 32(1):41-7. PubMed ID: 18978501
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cannabis; adverse effects from an oromucosal spray.
    Scully C.
    Br Dent J; 2007 Sep 22; 203(6):E12; discussion 336-7. PubMed ID: 17703180
    [Abstract] [Full Text] [Related]

  • 13. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial.
    Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D.
    Pain; 2007 Dec 15; 133(1-3):210-20. PubMed ID: 17997224
    [Abstract] [Full Text] [Related]

  • 14. Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
    Prescrire Int; 2009 Oct 15; 18(103):226. PubMed ID: 19882800
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens.
    Wymer JP, Simpson J, Sen D, Bongardt S, Lacosamide SP742 Study Group.
    Clin J Pain; 2009 Jun 15; 25(5):376-85. PubMed ID: 19454870
    [Abstract] [Full Text] [Related]

  • 16. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study.
    Yucel A, Ozyalcin S, Koknel Talu G, Kiziltan E, Yucel B, Andersen OK, Arendt-Nielsen L, Disci R.
    Eur J Pain; 2005 Aug 15; 9(4):407-16. PubMed ID: 15979021
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 15; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 18. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.
    Cannabis-In-Cachexia-Study-GroupDivision of Oncology/Hematology, Department of Internal Medicine, Cantonal Hospital, St Gallen, Switzerland. florian.strasser@kssg.ch, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T.
    J Clin Oncol; 2006 Jul 20; 24(21):3394-400. PubMed ID: 16849753
    [Abstract] [Full Text] [Related]

  • 19. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J.
    Clin Ther; 2006 May 20; 28(5):689-706. PubMed ID: 16861091
    [Abstract] [Full Text] [Related]

  • 20. [Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication].
    Svendsen KB, Jensen TS, Bach FW.
    Ugeskr Laeger; 2005 Jun 20; 167(25-31):2772-4. PubMed ID: 16014264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.